{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T04:38:43Z","timestamp":1777437523812,"version":"3.51.4"},"reference-count":26,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2010,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            In a previous study, it was found that the antibody response to a nonvaccine pertussis antigen in children who were vaccine failures was reduced compared with the response in nonvaccinated children who had pertussis. In two acellular pertussis vaccine efficacy trials in Sweden, we studied the convalescent-phase enzyme-linked immunosorbent assay (ELISA) geometric mean values (GMVs) in response to pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (PRN), and fimbriae (FIM 2\/3) in vaccine failures and controls with pertussis. In Germany, the antibody responses to\n            <jats:italic>Bordetella pertussis<\/jats:italic>\n            antigens PT, FHA, PRN, and FIM-2 were analyzed by ELISA according to time of serum collection after onset of illness in children with pertussis who were vaccine failures or who were previously unvaccinated. Antibody values were also compared by severity of clinical illness. In Sweden, infants who had received a PT toxoid vaccine and who were vaccine failures had a blunted response to the nonvaccine antigen FHA compared with the response in children who had received a PT\/FHA vaccine. Similarly, infants who had pertussis and who had received a PT\/FHA vaccine had a blunted response to the nonvaccine antigens PRN and FIM 2\/3 compared with the response in children who were vaccine failures and who had received a PT, FHA, PRN, and FIM 2\/3 vaccine. In Germany, in sera collected from 0 to 15 days after pertussis illness onset, the GMVs for all 4 antigens (PT, FHA, PRN, and FIM-2) were significantly lower in an unvaccinated group than in children who were diphtheria-tetanus-acellular pertussis (DTaP) vaccine failures. In the unvaccinated group, the GMV of the PT antibody rose rapidly over time so that it was similar to that of the DTaP vaccine recipients at the 16- to 30-day period. In contrast, the antibody responses to FHA, PRN, and FIM-2 at all time periods were lower in the diphtheria-tetanus vaccine (DT) recipients than in the DTaP vaccine failures. In both Sweden and Germany, children with less severe illness had lower antibody responses than children with typical pertussis. Our findings indicate that upon exposure and infection, previous vaccinees have more-robust antibody responses to the antigens contained in the vaccine they had received than to\n            <jats:italic>Bordetella<\/jats:italic>\n            antigens that were not in the vaccine they had received. In addition, over time the antibody responses to FHA, PRN, and FIM-2 were greater in children with vaccine failure (primed subjects) than in unvaccinated children (unprimed subjects) whereas the responses to PT were similar in the primed and unprimed children, as determined from sera collected after 15 days of illness. Our findings lend support to the idea that DTaP vaccines should contain multiple antigens.\n          <\/jats:p>","DOI":"10.1128\/cvi.00469-09","type":"journal-article","created":{"date-parts":[[2010,3,25]],"date-time":"2010-03-25T03:29:05Z","timestamp":1269487745000},"page":"741-747","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":43,"title":["Antibody Response Patterns to\n            <i>Bordetella pertussis<\/i>\n            Antigens in Vaccinated (Primed) and Unvaccinated (Unprimed) Young Children with Pertussis"],"prefix":"10.1128","volume":"17","author":[{"given":"James D.","family":"Cherry","sequence":"first","affiliation":[{"name":"David Geffen School of Medicine at UCLA and Mattel Children's Hospital UCLA, Los Angeles, California"},{"name":"Division of Pediatric Infectious Diseases, University Children's Hospital, Basel, Switzerland"},{"name":"Department of Microbiology, Immunology and Molecular Genetics, UCLA, Los Angeles, California"},{"name":"Norwegian Institute of Public Health, Oslo, Norway"},{"name":"Swedish Institute for Infectious Disease Control, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Heininger","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine at UCLA and Mattel Children's Hospital UCLA, Los Angeles, California"},{"name":"Division of Pediatric Infectious Diseases, University Children's Hospital, Basel, Switzerland"},{"name":"Department of Microbiology, Immunology and Molecular Genetics, UCLA, Los Angeles, California"},{"name":"Norwegian Institute of Public Health, Oslo, Norway"},{"name":"Swedish Institute for Infectious Disease Control, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Richards","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine at UCLA and Mattel Children's Hospital UCLA, Los Angeles, California"},{"name":"Division of Pediatric Infectious Diseases, University Children's Hospital, Basel, Switzerland"},{"name":"Department of Microbiology, Immunology and Molecular Genetics, UCLA, Los Angeles, California"},{"name":"Norwegian Institute of Public Health, Oslo, Norway"},{"name":"Swedish Institute for Infectious Disease Control, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jann","family":"Storsaeter","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine at UCLA and Mattel Children's Hospital UCLA, Los Angeles, California"},{"name":"Division of Pediatric Infectious Diseases, University Children's Hospital, Basel, Switzerland"},{"name":"Department of Microbiology, Immunology and Molecular Genetics, UCLA, Los Angeles, California"},{"name":"Norwegian Institute of Public Health, Oslo, Norway"},{"name":"Swedish Institute for Infectious Disease Control, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lennart","family":"Gustafsson","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine at UCLA and Mattel Children's Hospital UCLA, Los Angeles, California"},{"name":"Division of Pediatric Infectious Diseases, University Children's Hospital, Basel, Switzerland"},{"name":"Department of Microbiology, Immunology and Molecular Genetics, UCLA, Los Angeles, California"},{"name":"Norwegian Institute of Public Health, Oslo, Norway"},{"name":"Swedish Institute for Infectious Disease Control, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaretha","family":"Ljungman","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine at UCLA and Mattel Children's Hospital UCLA, Los Angeles, California"},{"name":"Division of Pediatric Infectious Diseases, University Children's Hospital, Basel, Switzerland"},{"name":"Department of Microbiology, Immunology and Molecular Genetics, UCLA, Los Angeles, California"},{"name":"Norwegian Institute of Public Health, Oslo, Norway"},{"name":"Swedish Institute for Infectious Disease Control, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans O.","family":"Hallander","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine at UCLA and Mattel Children's Hospital UCLA, Los Angeles, California"},{"name":"Division of Pediatric Infectious Diseases, University Children's Hospital, Basel, Switzerland"},{"name":"Department of Microbiology, Immunology and Molecular Genetics, UCLA, Los Angeles, California"},{"name":"Norwegian Institute of Public Health, Oslo, Norway"},{"name":"Swedish Institute for Infectious Disease Control, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","first-page":"955","year":"1988","unstructured":"Ad Hoc Group for the Study of Pertussis Vaccines. 1988. Placebo-controlled trial of two acellular pertussis vaccines in Sweden\u2014protective efficacy and adverse events. Lanceti:955-960.","journal-title":"Lancet"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0022-3476(05)82442-4","volume":"117","year":"1990","unstructured":"Blumberg, D. A., C. M. Mink, J. D. Cherry, K. S. Reisinger, M. M. Blatter, B. L. Congeni, C. L. Dekker, M. G. Stout, J. R. Mezzatesta, J. V. Scott, et al. 1990. Comparison of an acellular pertussis-component diphtheria-tetanus-pertussis (DTP) vaccine with a whole-cell pertussis-component DTP vaccine in 17- to 24-month-old children, with measurement of 69-kilodalton outer membrane protein antibody. J. Pediatr.117:46-51.","journal-title":"J. Pediatr."},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0022-3476(05)80727-9","volume":"119","year":"1991","unstructured":"Blumberg, D. A., C. M. Mink, J. D. Cherry, C. Johnson, R. Garber, S. A. Plotkin, B. Watson, G. A. Ballanco, R. S. Daum, B. Sullivan, et al. 1991. Comparison of acellular and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants. The APDT Vaccine Study Group. J. Pediatr.119:194-204.","journal-title":"J. Pediatr."},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1086\/381204","volume":"38","year":"2004","unstructured":"Cherry, J. D., D. X. L. Xing, P. Newland, K. Patel, U. Heininger, and M. J. Corbel. 2004. Determination of serum antibody to Bordetella pertussis adenylate cyclase toxin in vaccinated and unvaccinated children and in children and adults with pertussis. Clin. Infect. Dis.38:502-507.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/S0264-410X(98)00226-6","volume":"16","year":"1998","unstructured":"Cherry, J. D., J. Gornbein, U. Heininger, and K. Stehr. 1998. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine16:1901-1906.","journal-title":"Vaccine"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJM199602083340602","volume":"334","year":"1996","unstructured":"Gustafsson, L., H. O. Hallander, P. Olin, E. Reizenstein, and J. Storsaeter. 1996. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N. Engl. J. Med.334:349-355.","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1600-0463.2009.02530.x","volume":"117","year":"2009","unstructured":"Hallander, H. O., M. Ljungman, J. Storsaeter, and L. Gustafsson. 2009. Kinetics and sensitivity of ELISA IgG pertussis antitoxin after infection and vaccination with Bordetella pertussis in young children. APMIS117:797-807.","journal-title":"APMIS"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/j.1600-0463.2009.02521.x","volume":"117","year":"2009","unstructured":"Hallander, H. O., M. Ljungman, M. Jahnmatz, J. Storsaeter, L. Nilsson, and L. Gustafsson. 2009. Should fimbriae be included in pertussis vaccines? Studies on ELISA IgG anti-Fim 2\/3 antibodies after vaccination and infection. APMIS117:660-671.","journal-title":"APMIS"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1542\/peds.102.3.546","volume":"102","year":"1998","unstructured":"Heininger, U., J. D. Cherry, K. Stehr, S. Schmitt-Groh\u00e9, M. Uberall, S. Laussucq, T. Eckhardt, M. Meyer, J. Gornbein, and the Pertussis Vaccine Study Group. 1998. Comparative efficacy of the Lederle\/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pediatrics102:546-553.","journal-title":"Pediatrics"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0264-410X(94)90014-0","volume":"12","year":"1994","unstructured":"Heininger, U., J. D. Cherry, P. D. Christenson, T. Eckhardt, U. Goering, P. Jakob, W. Kasper, D. Schweingel, S. Laussucq, J. G. Hackell, et al. 1994. Comparative study of Lederle\/Takeda acellular and Lederle whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants in Germany. Vaccine12:81-86.","journal-title":"Vaccine"},{"key":"e_1_3_2_12_2","first-page":"402","year":"1999","unstructured":"Janeway, C. A. J., P. Travers, M. Walport, and J. D. Capra. 1999. Immunological memory, p. 402-413. In P. Austin and E. Lawrence (ed.), Immunobiology: the immune system in health and disease, 4th ed. Elsevier, New York, NY.","journal-title":"Immunobiology: the immune system in health and disease"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1097\/00006454-199711000-00007","volume":"16","year":"1997","unstructured":"Liese, J. G., C. K. Meschievitz, E. Harzer, J. Froeschle, P. Hosbach, J. E. Hoppe, F. Porter, S. Stojanov, K. Niinivaara, A. M. Walker, and B. H. Belohradsky. 1997. Efficacy of a two-component acellular pertussis vaccine in infants. Pediatr. Infect. Dis. J.16:1038-1044.","journal-title":"Pediatr. Infect. Dis. J."},{"key":"e_1_3_2_14_2","first-page":"388","year":"1986","unstructured":"Manclark, C. R., B. D. Meade, and D. G. Burstyn. 1986. Serologic response to Bordetella pertussis, p. 388-394. In N. R. Rose, H. Friedman, and J. L. Fahey (ed.), Manual of clinical laboratory immunology, 3rd ed. American Society for Microbiology, Washington, DC.","journal-title":"Manual of clinical laboratory immunology"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.18.2.326-382.2005"},{"key":"e_1_3_2_16_2","first-page":"322","year":"1990","unstructured":"Meade, B. D., C. M. Mink, and C. R. Manclark. 1990. Serodiagnosis of pertussis, p. 322-329. In C. R. Manclark (ed.), Proceedings of the Sixth International Symposium on Pertussis. DHHS publication no. (FDA) 90-1164. Department of Health and Human Services, United States Public Health Service, Bethesda, MD.","journal-title":"Proceedings of the Sixth International Symposium on Pertussis."},{"key":"e_1_3_2_17_2","unstructured":"Janeway's immunobiology 2008"},{"key":"e_1_3_2_18_2","first-page":"1569","volume":"350","year":"1997","unstructured":"Olin, P., F. Rasmussen, L. Gustafsson, H. O. Hallander, and H. Heijbel. 1997. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet350:1569-1577.","journal-title":"Ad Hoc Group for the Study of Pertussis Vaccines. Lancet"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0022-1759(95)00067-K","volume":"183","year":"1995","unstructured":"Reizenstein, E., H. O. Hallander, W. C. Blackwelder, I. Kuhn, M. Ljungman, and R. M\u00f6llby. 1995. Comparison of five calculation modes for antibody ELISA procedures using pertussis serology as a model. J. Immunol. Methods183:279-290.","journal-title":"J. Immunol. Methods"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/jama.1996.03530250041024","volume":"275","year":"1996","unstructured":"Schmitt, H. J., C. H. Wirsing von K\u00f6nig, A. Neiss, H. Bogaerts, H. Bock, H. Schulte-Wissermann, M. Gahr, R. Schult, J. U. Folkens, W. Rauh, and R. Clemens. 1996. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA275:37-41.","journal-title":"JAMA"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0264-410X(97)00100-X","volume":"15","year":"1997","unstructured":"Simondon, F., M. P. Preziosi, A. Yam, C. T. Kane, L. Chabirand, I. Iteman, G. Sanden, S. Mboup, A. Hoffenbach, K. Knudsen, N. Guiso, S. Wassilak, and M. Cadoz. 1997. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine15:1606-1612.","journal-title":"Vaccine"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/CDLI.5.2.130-134.1998"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1542\/peds.101.1.1","volume":"101","year":"1998","unstructured":"Stehr, K., J. D. Cherry, U. Heininger, S. Schmitt-Grohe, M. Uberall, S. Laussucq, T. Eckhardt, M. Meyer, R. Engelhardt, and P. Christenson. 1998. A comparative efficacy trial in Germany in infants who received either the Lederle\/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics101:1-11.","journal-title":"Pediatrics"},{"key":"e_1_3_2_24_2","first-page":"291","year":"1990","unstructured":"Storsaeter, J., H. O. Hallander, and C. P. Farrington. 1990. Evaluation of laboratory methods used for the diagnosis of pertussis infection and disease in the Swedish efficacy trial, p. 291-294. In C. R. Manclark (ed.), Proceedings of the Sixth International Symposium on Pertussis. DHHS publication no. (FDA) 90-1164. Department of Health and Human Services, United States Public Health Service, Bethesda, MD.","journal-title":"Proceedings of the Sixth International Symposium on Pertussis."},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0264-410X(98)00227-8","volume":"16","year":"1998","unstructured":"Storsaeter, J., H. O. Hallander, L. Gustafsson, and P. Olin. 1998. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine16:1907-1916.","journal-title":"Vaccine"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1086\/313707","volume":"30","year":"2000","unstructured":"Vincent, J. M., J. D. Cherry, W. F. Nauschuetz, et al. 2000. Prolonged afebrile non-productive cough illnesses in American soldiers in Korea: a serologic search for causation. Clin. Infect. Dis.30:534-539.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_27_2","first-page":"4","year":"1991","unstructured":"World Health Organization. 1991. WHO meeting on case definition of pertussis, Geneva, 10-11 January 1991, p. 4-5. MIM\/EPI\/PERT\/91.1. WHO, Geneva, Switzerland. http:\/\/whqlibdoc.who.int\/hq\/1991\/MIM_EPI_PERT_91.1.pdf .","journal-title":"WHO meeting on case definition of pertussis, Geneva, 10-11 January 1991"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00469-09","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00469-09","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:43:27Z","timestamp":1627591407000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00469-09"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["10.1128\/CVI.00469-09"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00469-09","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5]]},"assertion":[{"value":"2009-11-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-03-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}